Affiliations
Caterina E Faliti, Trinh T P Van, Fabliha A Anam, Narayanaiah Cheedarla, M Elliott Williams, Ashish Kumar Mishra, Sabeena Y Usman, Matthew C Woodruff, Geoff Kraker, Martin C Runnstrom, Shuya Kyu, Daniel Sanz, Hasan Ahmed, Midushi Ghimire, Andrea Morrison-Porter, Hannah Quehl, Natalie S Haddad, Weirong Chen, Suneethamma Cheedarla, Andrew S Neish, John D Roback, Rustom Antia, Jennifer Hom, Christopher M Tipton, John M Lindner, Eliver Ghosn, Surender Khurana, Christopher D Scharer, Arezou Khosroshahi, F Eun-Hyung Lee, Ignacio Sanz
DOI: 10.1038/s41590-024-02010-9
Abstract
Severe acute respiratory syndrome coronavirus 2 mRNA vaccination has reduced effectiveness in certain immunocompromised individuals. However, the cellular mechanisms underlying these defects, as well as the contribution of disease-induced cellular abnormalities, remain largely unexplored. In this study, we conducted a comprehensive serological and cellular analysis of patients with autoimmune systemic lupus erythematosus (SLE) who received the Wuhan-Hu-1 monovalent mRNA coronavirus disease 2019 vaccine. Our findings revealed that patients with SLE exhibited reduced avidity of anti-receptor-binding domain antibodies, leading to decreased neutralization potency and breadth. We also observed a sustained anti-spike response in IgD
Keywords
SLE,CD40,SARS-CoV-2
Related products
Catalog No. | Product Name | Description | Target |
---|---|---|---|
HB782016 | CD40 | Tumor necrosis factor receptor superfamily member 5, B-cell surface antigen CD40, Bp50, CD40L receptor, TNFRSF5, CDw40, CD40 |